Here are the 10-K annual reports from CNBX Pharmaceutical Inc (CNBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CNBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNBX filings page.
CNBX Pharmaceuticals Inc. (CNBX) is a Bethesda‑based, clinical‑stage biotech focused on cannabinoid‑based cancer therapies. The company’s lead candidates are Cannabics SR, an oral sustained‑release capsule for cancer anorexia‑cachexia syndrome (CACS), and RCC‑33, a cannabinoid formulation targeting colorectal cancer. Cannabics SR has shown weight gain and appetite benefits in a small peer‑reviewed pilot study, while RCC‑33 has reduced colorectal tumor volume in preclinical models. CNBX plans, contingent on new financing, to run Phase I/II(a) trials for both drugs starting in 2026 and estimates RCC‑33’s early human proof‑of‑concept program at about $6.5 million. The company has no significant revenue, outsources GMP manufacturing, and intends to monetize its pipeline mainly through partnerships and licensing rather than its own sales force. Its auditors have raised substantial doubt about CNBX’s ability to continue as a going concern, and the business depends heavily on raising additional capital and retaining a very small management team.